Compositions and methods to inhibit kidney stone growth
AssigneeKidney Stone Research Company, Inc.
InventorsGregory K. Hayer, Brendan Magrab, Henry R. Wolfe, Jr.
Life of this patent
Estimating the term…
Abstract
An oral dosage form or plurality of oral dosage forms comprising as active ingredients combinations of citric acid, magnesium citrate, phytin, pyridoxine, and musa is disclosed. The oral dosage form(s) is useful for inhibiting calcium oxalate crystal growth and for treating or inhibiting growth of kidney stones. Methods of inhibiting calcium oxalate crystal growth and of treating or preventing kidney stones are also disclosed.
Claims12
An oral dosage form or plurality of dosage forms comprising three ingredients selected from citric acid, magnesium citrate, phytin, pyridoxine, and musa, wherein the dosage form or plurality of dosage forms is selected from:
- a) an oral dosage form or plurality of dosage forms comprising about 102 mg to about 1052 mg citric acid, about 2.3 mg to about 227 mg magnesium citrate, and about 3.1 mg to about 600 mg phytin;
- b) an oral dosage form or plurality of dosage forms comprising about 101 mg to about 1051 mg citric acid, about 3.0 mg to about 600 mg phytin, and about 0.2 mg to about 15.1 mg pyridoxine;
- c) an oral dosage form or plurality of dosage forms comprising about 101 mg to about 1051 mg citric acid, about 0.2 mg to about 15.1 mg pyridoxine, and about 1.4 mg to about 252 mg musa;
- d) an oral dosage form or plurality of dosage forms comprising about 102 mg to about 1052 mg citric acid, about 3.0 mg to about 600 mg phytin, and about 1.5 mg to about 252 mg musa;
- e)
- f) an oral dosage form or plurality of dosage forms comprising about 101 mg to about 1052 mg citric acid, about 2.3 mg to about 226 mg magnesium citrate, and about 1.5 mg to about 251 mg musa;
- g) an oral dosage form or plurality of dosage forms comprising about 2.0 mg to about 227 mg magnesium citrate, about 3.0 mg to about 600 mg phytin, and about 0.2 mg to about 15.1 mg pyridoxine;
- h) an oral dosage form or plurality of dosage forms comprising about 2.0 mg to about 226 mg magnesium citrate, about 0.25 mg to about 15.1 mg pyridoxine, and about 1.4 mg to about 252 mg musa;
- i) an oral dosage form or plurality of dosage forms comprising about 2.0 mg to about 226 mg magnesium citrate, about 3.0 mg to about 600 mg phytin, and about 1.5 mg to about 252 mg musa;
- and
- j) an oral dosage form or plurality of dosage forms comprising about 3.0 mg to about 600 mg phytin, about 0.2 mg to about 15.1 mg pyridoxine, and about 1.5 mg to about 252 mg musa.
Dependencies are inferred from the claim text.